Novel Glu-based pyrazolo[3,4-d]pyrimidine analogues: design, synthesis and biological evaluation as DHFR and TS dual inhibitors

A novel series of multifunctional pyrazolo[3,4-d]pyrimidine-based glutamate analogs (6a-l and 7a,b) have been designed and synthesized as antifolate anticancer agents. Among the tested compounds, 6i exhibited the most potent anti-proliferative activity towards NSCLC, CNS, Ovarian, Prostate, Colon, Melanoma, Breast, and Renal cancers with good to weak cytostatic activity and non-lethal actions. 6i demonstrated higher selectivity for cancer than normal cells. 6i could significantly increase the accumulation of S-phase cells during the cell cycle distribution of cancer cells with high potency in the induction of apoptosis. The results unveiled that 6i probably acts through dual inhibition of DHFR and TS enzymes (IC₅₀ = 2.41 and 8.88 µM, correspondingly). Docking studies of 6i displayed that N1-p-bromophenyl and C3-Methyl groups participate in substantial hydrophobic interactions. The drug-likeness features inferred that 6i met the acceptance criteria of Pfizer. Taking together, 6i could be a promising prototype for further optimization as an effective anticancer drug.

Synthesis and Crystal Structure of Ethyl 5-(4-Bromophenyl)-7-methyl-3-oxo-2,3-dihidro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate

Thiazolopyrimidines are attractive to medical chemists as new antitumor agents due to their high inhibitory activity against the replication process of tumor cells and the easy modification of their structure by changing the number and nature of substituents. The presence of asymmetric C5 carbon atoms requires the development of racemic mixture separation procedures for these heterocycles. One of the most effective methods is the crystallization of a racemic compound in the form of a conglomerate. The prerequisite for such separation is the construction of chiral, supramolecular ensembles in the crystalline state. Halogen-π interactions were chosen as supramolecular synthons. In this context, ethyl 7-methyl-3-oxo-2,3-dihidro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate containing a 4-bromophenyl fragment at C5 was synthesized. The crystal structure of the resulting compound was established using SCXRD. The role of the halogen-π interaction on the formation of one-dimensional homochiral chains is revealed.

Neoteric deep eutectic solvents: history, recent developments, and catalytic applications

Deep eutectic solvents (DESs) are modified versions of ionic liquids (ILs) and are formed by the fusion of polar components (liquids or solids) via hydrogen bonding interactions. DESs are prepared by the simple mixing of two or three cheap constituents (that are capable of self-association) with gentle heating, which leads to a drastic decrease in their melting points. The resultant clear homogeneous mixture consists of cations, anions, as well as neutral molecules; this will contribute both ionic and molecular solvent properties to the DESs. DESs have emerged as alternatives to conventional organic solvents and ILs, which meet different criteria such as availability, low cost, low toxicity, biodegradability, recyclability, ease of preparation method, tunable, and designer physiochemical properties. Many of them have attracted considerable attention and haave been applied in distinct fields of chemistry. To summarize the full-scale development of DESs, this review discusses the history, classifications, various methods of preparation, properties, and some major applications in catalysis in the last three years. This review is expected to be helpful for the further development of DESs based on a summary of the fundamental research in the field.